Moderna stock was pacing toward its highest close in nearly two years on Friday. But the rally signaled more than an investor rotation away from tech and into defensive biopharma.

Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer Introduces in vivo CAR-T modality ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Moderna (MRNA) shares reached the highest level since March after the FDA issued comments that Jefferies said gave a “balanced” view on the company’s flu vaccine candidate, mRNA-1010, ahead of an ...

June 16 (Reuters) - Staff of the U.S. Food and Drug Administration said on Tuesday that data demonstrating a strong immune ‌response to Moderna's flu shot may support effectiveness in adults 65 years ...

Moderna (MRNA) on Tuesday said that Ester Banque, a former senior executive at Zoetis (ZTS) and Bristol Myers (BMY), will join the company as chief commercial officer as part of organizational changes ...

FDA's advisory committee will vote on June 18 whether mFlusiva benefits outweigh risks in older adults Moderna seeks accelerated approval of mFlusiva for adults 65 and older If approved, mFlusiva will ...

Moderna is restructuring its organization and leadership in preparation for a new wave of product launches, expanding President Stephen Hoge's role and appointing longtime pharma executive Ester ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. The company has hired Ester Banque as its chief commercial officer and has ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna’s seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in ...